NCT05360615进行中（未招募）1 期
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- MAKE365
研究概览
简要总结
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •post AKI stage 2-3
- •CrCl > 20
排除标准
- •pregnancy
- •post kidney transplant
- •previous use of SGLT2 Inhibitors
- •history of ketoacidosis
研究组 & 干预措施
Empagliflozin
Experimental
干预措施: Empagliflozin 10 MG (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
MAKE365
时间窗: 1 year
Major adverse kidney events (number of participants with death, renal replacement therapy, New CKD, CKD progression)
次要结局
未报告次要终点
研究者
Nattachai Srisawat ,M.D.
Assistant Professor.Nattachai Srisawat
Chulalongkorn University
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Effect of Empagliflozin in diabetic nephropathyephropathy and proteinuria in diabetic nephropathy patients taking empagliflozin.Diabetes mellitus due to underlying condition with diabetic nephropathyE08.21IRCT20210906052395N1Shahid Beheshti University of Medical Sciences96
招募中
4 期
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
招募中
2 期
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1Empagliflozin in Cardiorenal Syndrome Type 1NCT06030843Chulalongkorn University200
进行中（未招募）
1 期
Effect of treatment with Empagliflozin alone or in combination with Semaglutide on protein in the urine in persons with type 2 diabetes and elevated urinary protein.Type 2 diabetes with renal complicationsMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2019-003175-19-DKSteno Diabetes Center Copenhagen80
Unknown
4 期
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaType 2 Diabetes With Renal ManifestationsNCT04061200Steno Diabetes Center Copenhagen80